Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.

International journal of oncology

Volumn 24, Issue 5, 2004, Pages 1181-1188

  Mewani, Rajshree R ^a   Tang, Wenhua ^a   Rahman, Aquilur ^a   Dritschilo, Anatoly ^a   Ahmad, Imran ^a   Kasid, Usha N ^a   Gokhale, Prafulla C ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; LIPOSOME; PACLITAXEL; RAF PROTEIN;

ANIMAL; ARTICLE; BREAST TUMOR; CELL CULTURE; COMPARATIVE STUDY; DRUG SCREENING; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; PROSTATE TUMOR; TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RAF; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 6944243801     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.24.5.1181     Document Type: Article

References (0)